Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]Rüdiger Hehlmann, B Heinze, Andreas Hochhaus et al.|Blood|1994Cited by 458
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVRüdiger Hehlmann, Andreas Hochhaus, Martin C. Müller et al.|Journal of Clinical Oncology|2013Cited by 299
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study GroupRüdiger Hehlmann, A. Georgii, H. Heimpel et al.|Blood|1993Cited by 207
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemiaRüdiger Hehlmann, Aloïs Gratwohl, Christiane Falge et al.|Blood|2007Cited by 168